Closed the sale of LACER by ITALFARMACO

The pharmaceutical LACER has culminated his available process initiated after the strategic review made by the family after the premature demise of the president of LACER, the Mr. Don Helmut Andress. With a path of more than 70 years and a turnover in 2021 of more than 150 million Euros, LACER is one of the main Spanish actors in the segment of care of the health and personal hygiene.At present it is leader of market in practically all the segments in which it develops his activity, standing out the area bucodental with the mark LACER and other so stood out 4 marks like Thrombocid, Pilexil, Anso and Talquistina. Likewise, it has a wide wallet of medicines in the cardiovascular areas and uroginecológica. LACER, present in 18 countries, employs 476 people and has a production plant in Cerdanyola del Vallès that supplies both the national and international markets.ITALFARMACO will reinforce his presence in the attractive market of care of the health where already commercialises marks very consolidated like Natalben, Prodefen, Neuralex, Oniria, Aloclair Plus and Ainara. Likewise, it will allow to reinforce many of the areas of current business, in which ITALFARMACO already operates successfully from does more than 30 years, like the business of Medicines of Prescription and incorporate the plant of production of LACER in Cerdanyola, that together with which at present possesses ITALFARMACO in Alcobendas, will be an active important in the industrial operations of the Group.The price of the operation has not trascended although during this week had especulado with different offers around the 500 million part of five groups of the sector: Colgate, Stada, Cooper Pharma, Insud Pharma and the own Italfarmaco.The integration into ITALFARMACO will allow LACER to consolidate its leadership position in Spain through active investment in its current brands and the expansion of its product portfolio, generating a turnover of more than 1,000 million euros. Additionally, LACER will see its international growth boosted by benefiting from ITALFARMACO's global commercial network of subsidiaries and distributors.In words of the Dr. Francesco Of Santis, President of ITALFARMACO, "The incorporation of the business, of the marks and of the talent of the personnel of LACER supposes an important reinforcement to our company in Spain, and gives continuity to the spirit of growth sustained of ITALFARMACO, with the aim to lead the different areas of business in which we are presents, and contribute new therapeutic alternatives that improve the health of the people".In words of the Family Andress, shareholders of LACER, "LACER will benefit of the support of a new partner experienced that will allow to both companies grow jointly to the creation of a pharmaceutical leader European. Said integration will allow to LACER continue with his history of success and guarantee that the legacy that began does more than 70 years perdure in thetime ".

Closed the sale of LACER by ITALFARMACO

After several days of speculation, the pharmaceutical company has finally announced that it already has a buyer